Avaca Pharma Profile
Key Indicators
- Authorised Capital ₹ 25.00 Cr
as on 17-07-2024
- Paid Up Capital ₹ 11.97 Cr
as on 17-07-2024
- Company Age 8 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 3164.95%
(FY 2022)
- Profit -49.14%
(FY 2022)
- Ebitda 219.49%
(FY 2022)
- Net Worth -1.56%
(FY 2022)
- Total Assets 8.63%
(FY 2022)
About Avaca Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 25.00 Cr and a paid-up capital of Rs 11.97 Cr, as per Ministry of Corporate Affairs (MCA) records.
Mahesh Kandula, Apparsundaram Kandaswamy, and Sridhar Koganti serve as directors at the Company.
- CIN/LLPIN
U74999AP2016PTC104239
- Company No.
104239
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 Oct 2016
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Vijayawada
Industry
Company Details
- Location
Guntur, Andhra Pradesh, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Avaca Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mahesh Kandula  | Director | 04-Jul-2020 | Current |
| Apparsundaram Kandaswamy | Director | 18-Jul-2020 | Current |
| Sridhar Koganti | Additional Director | Current |
Financial Performance of Avaca Pharma.
Avaca Pharma Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 3164.95% increase. The company also saw a substantial fall in profitability, with a 49.14% decrease in profit. The company's net worth dipped by a decrease of 1.56%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Avaca Pharma?
In 2022, Avaca Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Cellix Bio Pharma Private LimitedActive 4 years 11 monthsMahesh Kandula and Sridhar Koganti are mutual person
Cellix Bio Private LimitedActive 10 years 7 monthsMahesh Kandula and Sridhar Koganti are mutual person
Vclinbio Pharmaceuticals Private LimitedActive 7 years 10 monthsApparsundaram Kandaswamy is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Avaca Pharma?
Unlock and access historical data on people associated with Avaca Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Avaca Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Avaca Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
